Loading...
Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
Background/Aim: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. Patients and Methods: We...
Na minha lista:
| Udgivet i: | In Vivo |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
International Institute of Anticancer Research
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7652488/ https://ncbi.nlm.nih.gov/pubmed/32871820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12108 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|